NEBUPENT (pentamidine isethionate) by Fresenius Kabi is clinical pharmacology: microbiology mechanism of action studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of dna, rna, phospholipid and protein synthesis. First approved in 1989.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
NEBUPENT (pentamidine isethionate) is an inhaled antiprotozoal agent that interferes with microbial nuclear metabolism by inhibiting DNA, RNA, phospholipid, and protein synthesis. It is indicated for Pneumocystis jiroveci pneumonia (PJP) prophylaxis and treatment in immunocompromised patients, particularly those with AIDS. The drug achieves high lung concentrations via aerosol delivery while maintaining minimal systemic exposure.
As a 35-year-old product approaching loss of exclusivity, NEBUPENT represents a legacy brand with declining growth; commercial teams are typically smaller and focused on retention rather than expansion.
CLINICAL PHARMACOLOGY: Microbiology Mechanism of Action Studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of DNA, RNA, phospholipid and protein synthesis. However, the mode of action is not fully understood. Activity in vitro and in vivo…
Worked on NEBUPENT at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NEBUPENT offers deep expertise in specialty/infectious disease and lifecycle management within a niche, mature product portfolio under Fresenius Kabi. Career value lies in mastering mature product defense, payer negotiations, and optimization of a legacy inhalation platform rather than blockbuster growth.